Pharma BD Deal Intelligence
A $1.7B Roche acquisition of Ignyta that expanded its precision oncology pipeline in cancer targeted therapies. The deal gave Roche another entry in the biomarker-driven oncology race, though limited disclosed terms leave the full commercial payoff unclear.
Roche acquired Ignyta for ~$1.7B for cancer targeted therapies.
Roche snaps up Ignyta and entrectinib for $1.7 billion at $27 per share a 74 percent premium.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche acquired Ignyta for ~$1.7B for cancer targeted therapies.
5K US cases/yr · $800M Global ROS1/TRK Inhibitor Market (2018) · 1-2% NSCLC Patients with ROS1 Fusion
ROS1 and NTRK gene fusions are oncogenic drivers across multiple tumor types. Entrectinib was a CNS-penetrant inhibitor of ROS1 and TRK fusions, addressing brain metastases.
Entrectinib approved as Rozlytrek in Aug 2019 for ROS1+ NSCLC and NTRK fusions. CNS penetration differentiated it from crizotinib.
Roche completed ~$1.7B acquisition of Ignyta, gaining entrectinib, a ROS1/NTRK inhibitor for NSCLC and NTRK-positive solid tumors.
FDA approved Rozlytrek for ROS1+ NSCLC and NTRK fusion+ solid tumors, giving Roche precision oncology asset across multiple tumor types.
Rozlytrek secured dual approvals and generates niche precision oncology revenue. $1.7B reasonable for multi-tumor biomarker-driven drug, though market inherently limited.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Ignyta Inc. (this deal) | 2017 | $1.7B | 73 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2017 deals · Roche Holding AG deals · Oncology deals